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Reduction in Late-Stage Breast Cancer Incidence in the
Mammography Era
Implications for Overdiagnosis of Invasive Cancer
Mark A. Helvie, MD1; Joanne T. Chang, MPH2; R. Edward Hendrick, PhD3; and Mousumi Banerjee, PhD4
BACKGROUND: Mammographic screening is expected to decrease the incidence of late-stage breast cancer. In the current study, the
authors determined the decrease in late-stage cancer incidence and the changes in invasive cancer incidence that occurred in the
mammographic era after adjusting for prescreening temporal trends. METHODS: Breast cancer incidence and stage data were
obtained from the Surveillance, Epidemiology, and End Results program. The premammography period (1977-1979) was compared
with the mammographic screening period (2007-2009) for women aged40 years. The authors estimated prescreening temporal
trends using 5 measures of annual percentage change (APC). Stage-specific incidence values from 1977 through 1979 (baseline) were
adjusted using APC values of 0.5%, 1.0%, 1.3%, and 2.0% and then compared with observed stage-specific incidence in 2007 through
2009. RESULTS: Prescreening APC temporal trend estimates ranged from 0.8% to 2.3%. The joinpoint estimate of 1.3% for women
aged40 years approximated the 4-decade long APC trend of 1.2% noted in the Connecticut Tumor Registry. At an APC of 1.3%,
late-stage breast cancer incidence decreased by 37% (56 cases per 100,000 women) with a reciprocal increase in early-stage rates
noted from 1977 through 1979 to 2007 through 2009. Resulting late-stage cancer incidence decreased from 21% at an APC of 0.5%
to 48% at an APC of 2.0%. Total invasive breast cancer incidence decreased by 9% (27 cases per 100,000 women) at an APC of 1.3%.
CONCLUSIONS: There is evidence that a substantial reduction in late-stage breast cancer has occurred in the mammography era
when appropriate adjustments are made for prescreening temporal trends. At background APC estimates of 1%, the total invasive
breast cancer incidence also decreased. Cancer 2014;120:2649-56. VC 2014 American Cancer Society.
KEYWORDS: mammography, screening, overdiagnosis, breast cancer, late-stage disease.
INTRODUCTION
Breast cancer is a major worldwide health problem and the most common cause of female cancer death. In 2008, 1.4 mil-
lion women were diagnosed with breast cancer and 458,000 died of the disease worldwide.1 Mammographic screening
can reduce breast cancer mortality. A recent meta-analysis of 8 randomized trials demonstrated a 14% to 32% mortality
reduction among women invited to be screened compared with women who were not invited.2 A meta-analysis of women
participating in organized clinical screening programs showed a 49% mortality reduction.3 The Cancer Intervention and
SurveillanceModeling Network (CISNET) models of annual screening beginning at age 40 years demonstrated a 40% av-
erage reduction in breast cancer mortality.4 Even with these substantial benefits, however, mammographic screening
remains controversial and trade-offs between benefit and harms are debated.
Successful screening programs are expected not only to detect small early-stage cancer but to decrease the incidence
of higher-mortality late-stage disease. Many organized mammographic screening programs have demonstrated a shift
from late-stage to early-stage disease detection.5-10 Results from the United States, which lacks a national screening pro-
gram, have shown a greater increase in early-stage disease incidence compared with late-stage disease reduction in breast
cancer.11-13 Recently, Bleyer andWelch used Surveillance, Epidemiology, and End Results Program (SEER) breast cancer
incidence data, which included both screened and unscreened women, to demonstrate a 69% increase in localized disease
but only an 8% decrease in late-stage disease over a 30-year interval from 1976 through 1978 to 2006 through 2008.13
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Questions were raised whether screening mammography
had met the fundamental requirement of decreasing late-
stage disease. However, stage-specific incidence results
were not adjusted for the underlying temporal trend of
increasing breast cancer incidence that existed before the
introduction of widespread screening mammography in
the United States in the mid-1980s. Breast cancer inci-
dence increased 1% to 3% per year in the United States
and Europe before the advent of mammography screen-
ing.14-20 In the United States, the annual incidence
increased approximately 1.2 % (annual percentage change
[APC]) in the long-standing Connecticut Tumor Registry
from 1940 to 1982.16-18,21,22 More rapid increases, up to
5% per year, have been documented in the absence of
screening mammography in Asia, Africa, and Eastern
Europe.1,14,23,24
Although these underlying temporal trends absent
screening mammography may appear small on an annual
basis, their impact on expected future incidence over
many decades is profound, independent of interventions
such as screening mammography. These trends directly
influence calculations of late-stage disease changes and
estimates of overdiagnosis. Over 30 years, a 1% annual
increase results in an incidence increase of 33% and a 2%
annual increase results in an overall incidence increase of
78% due to compounding. The projected incidence of
early-stage and late-stage disease as well as total breast can-
cer incidence will be much larger in the future given those
underlying temporal trends, independent of screening.
In the current study, we sought to determine the
effect on late-stage breast cancer incidence and total inva-
sive breast cancer incidence in the United States after
adjusting for temporal trends by comparing SEER registry
data from the prescreening era of 1977 through 1979 to
the screening era of 2007 through 2009. Baseline inci-
dence values in 1977 through 1979 were projected to the
period from 2007 through 2009 using a range of APCs.
We then compared the projected values with actual
observed values in 2007 to 2009. We used 5 different
APC estimates derived from the following sources: his-
toric female premammographic screening data from the
Connecticut Tumor Registry from 1940 to 1982, SEER
data for women aged 40 years from 1977 to 1982,
SEER data for men aged 40 years from 1977 to 2009,
SEER data for women aged< 40 years from 1977 to
1984, and United Kingdom female cancer registry data
from 1975 to 1987. We calculated changes in early-stage,
late-stage, and total invasive breast cancer rates between
1977 through 1979 and 2007 through 2009 after making
these underlying temporal trend adjustments.
MATERIALS AND METHODS
Determinations of Annual Percentage Change in
Breast Cancer Incidence
Previous analyses of Connecticut Tumor Registry inci-
dence trends from 1940 through 1982 have shown an
APC of 1.16%18 with age-specific APC values ranging
from 0.8% for women aged 40 years to 49 years to 1.51%
for women aged 60 years to 69 years.21 When adjusted for
period and cohort effect, the APC was 1.67%.16 Age-
adjusted breast cancer incidence increased from 83.4 per
100,000 women in 1936 through 1940 to 131.2 per
100,000 women in 1976 through 1978.17
Breast cancer incidence data in the United States
from 1977 to 2009 were obtained from the population-
based registries that participate in the National Cancer
Institute’s SEER program.25 We extracted reported breast
cancer cases by age and stage of disease in 18 SEER geo-
graphic areas, which captured cancer data from 27.8% of
the US population.26 Tumor stage was categorized as
localized, regional, and distant. Individuals with ductal
carcinoma in situ (DCIS) were determined using 14 codes
from the 3rd edition of the International Classification of
Diseases for Oncology (8500/2, 8501/2, 8502/2, 8503/2,
8504/2, 8507/3, 8508/2, 8510/2, 8521/2, 8522/2, 8523/
2, 8540/2, 8541/2, and 8543/2) for in situ groups, but we
excluded lobular carcinoma in situ. United States breast
cancer incidence trends were analyzed and categorized
into 3 groups: women aged 40 years, women aged< 40
years, and men aged 40 years. In addition, female breast
cancer incidence in the United Kingdom from Cancer
Research UK was reviewed.27
Statistical Analysis
To characterize trends in age-adjusted incidence rates, we
performed joinpoint regression analyses using Joinpoint
statistical software (version 3.5; Surveillance Research
Program, National Cancer Institute, Bethesda, MD).
Joinpoint regression allows for the identification of statis-
tically significant changes in trends and the estimation of
the annual percentage rate of change in each trend inter-
val. Joinpoint analysis was performed by group (women
aged 40 years, women aged< 40 years, and men
aged 40 years) and stage of disease (DCIS, localized, re-
gional, and distant). We analyzed joinpoint trends and
APCs from the prescreening era: 1977 through 1982 for
women aged 40 years, 1977 through 1984 for women
aged< 40 years (1984 was used instead of 1982 because
the joinpoint result demonstrated a natural breakpoint at
1984), and 1975 to 1987 for women in the United King-
dom (national screening began in 1988 in the UK) overall
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and by age group.28 We used 1977 through 2009 for men
aged 40 years. Male incidence trends were reviewed
because they represented the longest-duration unique
SEER population that had never been recommended for
screening. The APC in age-adjusted incidence was calcu-
lated from joinpoint analyses. Based on the obtained APC
estimates, we assumed 4 APCs of 0.5%, 1.0%, 1.3%, and
2.0% for underlying temporal trend adjustments in
incidence.
Incidence Estimates
Unadjusted trends for stage-specific SEER breast cancer
incidence values were averaged over the 3-year period of
1977 through 1979 for each stage of disease to produce
baseline prescreening values. Similarly, unadjusted stage-
specific incidence values from the screening period of
2007 through 2009 were averaged to produce an
observed value. We then adjusted the baseline value for
1977 through 1979 for APC values of 0.5%, 1.0%,
1.3%, and 2.0% to produce a “projected” incidence
value by applying the APC for 30 years for each disease
stage. These would be the expected incidence values for
each breast cancer stage if only the underlying trend in
APC continued for 30 years. We compared the pro-
jected values with observed values in 2007 through
2009 and reported the change in the number of cases
per 100,000 women as well as the percentage change,
defined as the change in incidence divided by projected
incidence multiplied by 100%. We grouped DCIS and
localized breast cancer as early-stage disease and regional
and distant breast cancer as late-stage disease. Finally,
we compared the projected incidence versus the
observed incidence for each APC for invasive breast can-
cer alone and for all breast cancer (invasive cancer plus
DCIS).
RESULTS
The APC estimates for each of the 5 methods are shown
in Table 1. The 1.3% APC for women aged 40 years
approximates the 4-decade historic Connecticut Tumor
Registry trend of 1.2% and is considered a central esti-
mate. Overall, APC values ranged from 0.8% for men
aged 40 years to 2.3% for UK women aged 70 years.
The 1.3% APC for US women is less than the APC of
1.7% for UK women, the annual rate of incidence
increase observed overall in UK women from 1976 to
1987.
Table 2 provides mean age-adjusted SEER breast
cancer incidence rates, unadjusted for underlying tempo-
ral trend increase, for the periods of 1977 through 1979
and 2007 through 2009 for women aged 40 years.
When unadjusted for underlying temporal trend increase,
these rates demonstrated a marked increase in early-stage
disease (DCIS and localized breast cancer) with an
TABLE 1. Breast Cancer Temporal Trends Prior to Mammographic Screening
Group Years Initial Incidencea Final Incidencea APC 95% CI
Connecticut Tumor Registry 1940-1982 Literatureb 1.2 —
SEER: women aged 40 y 1977-1982 212.6 226.7 1.3 0.2-2.4
SEER: men aged 40 y 1977-2009 2.3 3.1 0.8 0.5-1.1
SEER: women aged <40 y 1977-1984 13.4 14.9 1.9 0.4-3.4
United Kingdom: women aged >15 y 1976-1987 71.8 89.7 1.7 1.4-2.0
15-39 y 15.8 17.9 1.1 0.7-1.6
40-49 y 118.5 130.5 0.7 0.4-1.0
50-64 y 152.8 195.1 2.1 1.9-2.3
65-69 y 192.4 235.1 1.8 1.6-2.0
70 y 227.5 286.1 2.3 2.1-2.4
Abbreviations: 95% CI, 95% confidence interval; APC, annual percent change; SEER, Surveillance, Epidemiology, and End Results.
a Incidence indicates the number of cases per 100,000 women.
b See text.
TABLE 2. Incidencea of Stage-Specific Breast Can-
cer Among Women Aged 40 Years, Unadjusted
for Underlying Breast Cancer Temporal Trends
Increase
1977 to
1979
2007 to
2009
Absolute
Change
%
Change
Early stage
DCIS 6.3 58.4 52.1 827
Localized disease 106.6 181.2 74.7 70
Total 112.9 239.6 126.8 112
Late stage
Regional 86.5 77.2 29.3 211
Distant 16.8 17.7 0.9 5
Total 103.3 94.9 28.4 28
Total invasive cancer 209.9 276.2 66.3 32
Total breast cancer 216.2 334.6 118.4 55
Abbreviation: DCIS, ductal carcinoma in situ.
a Incidence indicates the number of cases per 100,000 women.
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associated small decrease in late-stage disease (regional
and distant breast cancer). Localized disease was found to
increase by 74.7 cases per 100,000 women or 70%,
whereas late-stage disease decreased by 8.4 cases per
100,000 women or 8%. In addition, there was an increase
in the incidence of invasive and total cancer noted when
no adjustment was made for prescreening temporal
trends.
The projected stage-specific incidence rates derived
from Table 2 after adjusting for prescreening temporal
trends are shown in Table 3. These would be the expected
incidences if no factor other than the prescreening tempo-
ral trends continued over the 30-year period. At an APC
of 1.3%, the regional disease incidence value for 1977
through 1979 would be projected to increase from 86.5 to
126.8 cases per 100,000 women exclusively due to contin-
uation of the premammography underlying temporal
trend. Similarly, at an APC of 1.3%, the projected local-
ized disease incidence value would increase from 106.6
cases per 100,000 women to 152.6 cases per 100,000
women.
Table 4 shows stage-specific differences between
projected and observed incidence values for 2007 through
2009 for various APCs. At an APC of 1.3%, late-stage dis-
ease decreased 37% from the projected rate (150.8 cases
to 94.9 cases per 100,000 women). There were 55.8 cases
per 100,000 fewer women with late-stage disease noted
between 2007 and 2009 than at the baseline of 1977
through 1979. There was a similar but reciprocal increase
in the incidence of early-stage disease of 48% (difference
of 77.9 cases per 100,000 women). It is interesting to note
TABLE 3. Projected Incidencea of Stage-Specific
Breast Cancer Among Women Aged 40 Years
From 1977 Through 1979 to 2007 Through 2009,
Adjusted for Underlying Temporal Trends
1977 to
1979 Projected 2007 to 2009
Baseline
APC
of 0.5%
APC of
1.0%
APC of
2%
APC of
1.3%
Early stage
DCIS 6.3 7.7 8.4 11.2 9.2
Localized disease 106.6 121.3 144.0 186.4 152.6
Total 112.9 129.0 148.4 197.6 161.8
Late stage
Regional 86.5 100.7 116.3 154.8 126.8
Distant 16.8 19.1 22.0 29.3 24.0
Total 103.3 119.8 138.4 184.1 150.8
Abbreviations: APC, annual percent change; DCIS, ductal carcinoma in
situ.
a Incidence indicates the number of cases per 100,000 women.
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that the majority of the early-stage increase is due to an
increase in the incidence rate of DCIS (49.2 cases per
100,000 women compared with a localized breast cancer
rate increase of 28.6 cases per 100,000 women). Across all
APC estimates, decreases in late-stage disease ranged from
21% at an APC of 0.5% to a 48% decrease at an APC of
2.0%. Figure 1 shows the marked decline in late-stage
breast cancer incidence with increasing estimates of APC.
Table 4 also provides estimates of changes in inva-
sive cancer incidence in the mammographic era. At an
APC of 1.3%, there were 9% (27.2 cases per 100,000
women) fewer women with invasive breast cancer between
2007 through 2009 than expected. Even at an APC of
1%, a value below all APC estimates except for males,
there were 1% fewer invasive breast cancer cases than
expected. At an APC of 2%, which approximates the UK
trend, there were 26% fewer invasive breast cancer cases in
2007 through 2009 than expected. Total breast cancer
incidence (invasive cancer plus DCIS) demonstrated a 7%
increase over the 30-year period for an APC of 1.3% and
a 12% decrease for an APC of 2%. Figure 2 shows the
relationship between the percentage changes for invasive
cancer and all breast cancer between 1977 and 1979 and
2007 and 2009 by APC estimates. At background APC
estimates of 1%, a decrease in the incidence of invasive
breast cancer was noted. The total breast cancer (invasive
breast cancer plus DCIS) incidence increase noted
between 1977 and 1979 and 2007 and2009 is entirely
accounted for by the background incidence trend for an
APC of> 1.5%.
DISCUSSION
The results of the current study demonstrate a substantial
reduction in the incidence of late-stage breast cancer in
US women in the mammography era when adjusted for
temporal trends in incidence observed in the prescreening
era. Increases in the incidence of early-stage disease are
associated with the decrease in late-stage incidence, the
expected finding of mammographic screening. At a cen-
tral APC of 1.3%, a 37% reduction in late-stage disease
was observed, with a reciprocal increase in early-stage dis-
ease. This decrease in late-stage disease approximates the
breast cancer mortality reduction observed among women
in the United States from 1990 through 2009.
The current study results also demonstrate an overall
decrease in the incidence of invasive cancer at APC esti-
mates of 1%. At first inspection, the data in Table 2,
which does not adjust for underlying temporal trends,
would suggest there was a good deal of excess breast cancer
incidence from 2007 through 2009 compared with 3 dec-
ades earlier. However, an adjustment for underlying tem-
poral trends is essential in making such a comparison and
conclusion. After appropriate APC adjustments based on
5 different methods, we demonstrated that the conclusion
of a large excess invasive cancer incidence drawn from
unadjusted breast cancer incidence values is not sup-
ported. To the contrary, at the central APC estimate of
1.3%, there was a 9% reduction (27 cases per 100,000
Figure 1. Reduction in late-stage breast cancer incidence is
shown among women aged40 years from 1977 through
1979 to 2007 through 2009 by annual percent change (APC)
estimates of prescreening temporal trends.
Figure 2. Percent change of breast cancer incidence between
1977 through 1979 and 2007 through 2009 by annual percent
change (APC) estimate is shown for invasive breast cancer
and all breast cancers among women aged40 years.
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women) in invasive cancer incidence. This means 27 of
every 100,000 women were potentially spared the devel-
opment of invasive cancer and its associated morbidity
and mortality in each year from 2007 through 2009. The
reduction in invasive cancer incidence is consistent with
disruption of the nonobligatory pathway from DCIS to
invasive breast cancer through the detection and treat-
ment of DCIS in some women. At an APC of 1.3%, the
total breast cancer incidence increased by 7% over 30
years but this small overall incidence increase should not
be construed to represent an overdiagnosis rate, because
the change in overall breast cancer incidence would be
reduced when adjusted for lead time.29 This observation
of a low rate of potential overdiagnosis is consistent with a
recent Euroscreen analysis of 13 overdiagnosis studies that
demonstrated a low level of overdiagnosis (1%-10%)
when appropriate adjustments for temporal trends, risk
factors, and lead time were considered.30 The results of
the current study differ distinctly from those of Bleyer and
Welch, who estimated overdiagnosis at a rate of 31% but
used an APC value of only 0.25%.13 The APC they used
is less than the various estimates of APC we obtained in
the absence of screening mammography. At APC values
of> 1.5%, such as the incidence trends observed in the
United Kingdom in the 1980s, there is an overall reduc-
tion in the total breast cancer burden.
The shift from late-stage to early-stage disease in the
current analysis has been reported in many organized
screening programs.5-10 Foca et al recently reviewed the
Italian screening experience and demonstrated a 29%
reduction in the diagnosis of pT2 to pT4 tumors at 7 to 8
years after the introduction of organized screening.7 In
the United States, studies have demonstrated a marked
increase in early-stage disease with disproportionately
small decreases in late-stage disease using tumor registry
data over 60-year and 30-year periods but have not
adjusted for temporal trends.12,13
Breast cancer incidence had increased 1% to 3% per
year in the United States and Western Europe before
mammography screening.14,15,18 The longest-standing
US tumor registry shows an APC of 1.2% from 1940
through 1982.18 In the United Kingdom, APC values of
1% to 2% were reported, a finding that is in keeping with
the current analysis.6,19,28 Larger incidence increases have
occurred in regions of Eastern Europe, Asia, Africa, and
Latin America without mammographic screening.1 From
1973 through 1999, Hong Kong had an age-standardized
APC increase of 3.6%.23 Zimbabwe observed a 4.9%
APC increase from 1991 through 2010.24 Longstanding
reproductive, dietary, and environmental factors associ-
ated with increased breast cancer risk are commonly cited
as reasons for the increases now observed globally.1,14
An accurate APC estimate is critical for determining
projected incidence and overdiagnosis. We have provided
a range of APC values (with a central value of 1.3%) rather
than a single number, because to the best of our knowl-
edge direct measures of age-matched control APC values
during the study period between 1977 and 2009 are not
available. Each APC estimate has strengths and limita-
tions. The 4-decade APC trend of 1.2% from the Con-
necticut Tumor Registry is unique in its long duration
and quality and is frequently cited as a US trend line. The
joinpoint trend for women aged 40 years noted between
1977 and 1982 is relatively short in duration but includes
the target population and uses complete SEER data. The
calculated 1.3% APC for this target group of women
closely approximates the historic Connecticut Tumor
Registry APC but is lower than more recent UK trends of
1.7%, which extended to the late 1980s. The longest
SEER trend line for unscreened individuals is for men,
but obvious differences in biology limit its use as an exclu-
sive measure. Even for males, an APC of nearly 1% was
observed. The trend lines for women aged< 40 years
showed a joinpoint APC of 1.9% for the premammo-
graphic screening period (1977-1984), but there was het-
erogeneity in later-year trends, including a 21.3% APC
from 1984 through 1994 and a 0.7% APC from 1994
through 2009. The trend among young females may not
be directly applicable to older women due to different
cancer biology. Results from the United Kingdom have
demonstrated significantly lower APC values for women
aged< 40 years (an APC of 1.1%) compared with older
women (with APCs of 1.8%-2.3%). Also confounding
the analysis for younger US women, mammographic
screening was recommended to begin at age 35 years by
some organizations during the study period. The prescre-
ening UK data from 1976 through 1987, which overlap
the first decade of our study period, may reflect more
recent temporal trends but are not matched to the US
population. The possibility of accelerating background
temporal trends for disease of distant stage in more recent
years is supported by a study that demonstrated an overall
APC of 2.1% from 1973 through 2009, but a greater
APC of 3.6% during 2000 to 2009 for US women
aged< 40 years.31 We applied APC projections equally
across all stages of disease. It is possible that APC trends
may vary by disease stage.
The initiation of large-scale opportunistic mammo-
graphic screening in the United States in the mid-1980s is
the most probable cause for the decrease in late-stage
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disease and the corresponding increase in early-stage dis-
ease. However, it is unlikely that mammography is the
sole etiology. Because SEER does not track the mode of
detection, we can only postulate the correlation with
screening mammography. Breast self-examination, clini-
cal breast examination, and an overall heightened aware-
ness of breast cancer may also have contributed.
Mammographic screening use increased rapidly in the late
1980s from< 5% before 1984 to 17% in 1987 and 33%
by 1990.18,32 More recently, 52% to 70% of women
aged 40 years have self-reported having had a mammo-
gram within the last 2 years. It is worth noting that the
actual use of screening mammography has been shown to
be 15% to 25% lower due to overestimates from self-
reporting.33
The results of the current study may underestimate
the positive impact of screening, which is not captured by
the broad SEER stage categories due to SEER’s inclusion
of both screened and unscreened women along with
changes in methods of diagnosis and stage determination.
Downsizing within stage of disease occurs by screening
mammography.10 Within the localized stage, downsize
migration and not treatment advances was responsible for
61% of the observed improvement in disease stage specific
survival over a 20-year period.34 Sentinel lymph node
sampling, which began during the 1990s, resulted in
upstaging of lymph node disease. Imaging improvements
can now detect more distant disease at the time of presen-
tation. These factors would increase more recent rates of
regional and distant disease incidence and cause underesti-
mation of late-stage incidence declines.
Conclusions
There is evidence of a substantial reduction in the inci-
dence of late-stage breast cancer, with a corresponding
shift toward early-stage disease, in the mammographic era
when appropriately adjusted for prescreening temporal
trends. At central APC estimates, a reduction in total inva-
sive breast cancer incidence is observed. Because mammo-
graphic screening is underused in the United States, there
may be the potential to reduce the incidence of late-stage
disease and invasive cancer further with the increased use
of screening mammography.
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